News for Akari Therapeutics Stock (AKTX)

Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

GlobeNewsWire • 12/11/20

Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease

GlobeNewsWire • 12/03/20

Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29

GlobeNewsWire • 10/27/20

Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia

GlobeNewsWire • 10/06/20

Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid

GlobeNewsWire • 10/01/20

Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Education Conference

GlobeNewsWire • 09/29/20

Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress

GlobeNewsWire • 09/01/20

Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia

GlobeNewsWire • 08/31/20

Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan

GlobeNewsWire • 08/12/20

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC

GlobeNewsWire • 07/01/20

Akari Therapeutics Announces Appointment of Chief Financial Officer

GlobeNewsWire • 07/01/20

Akari Therapeutics Reports First Quarter 2020 Financial Results and Highlights Recent Clinical Progress

GlobeNewsWire • 05/29/20

Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid

GlobeNewsWire • 05/21/20

Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients

GlobeNewsWire • 05/01/20

Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement

GlobeNewsWire • 03/04/20

Akari Therapeutics, Plc Announces Private Placement

GlobeNewsWire • 02/20/20

Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases

GlobeNewsWire • 01/27/20

Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study

GlobeNewsWire • 01/10/20

Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND

GlobeNewsWire • 12/23/19

Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial

GlobeNewsWire • 10/14/19

Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress

GlobeNewsWire • 10/10/19

Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference

GlobeNewsWire • 09/18/19

Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

Zacks Investment Research • 09/16/19

Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid

GlobeNewsWire • 09/13/19

Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September

GlobeNewsWire • 09/03/19